Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | RAF1 | P04049 | 4/20 | 0.43 |
| ▸ | UBE2M | P61081 | 4/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | ARAF | P10398 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686567 | 0.94 | RAF1 (0.40) | EPHX2RAF1UBE2MDCUN1D1KDR | |
| SCHEMBL4233284 | 0.90 | CCR3 (0.45) | EPHX2KDRBRAFFGFR1CCR3 | |
| SCHEMBL4236318 | 0.90 | MCHR1 (0.39) | KDRFGFR1CCR3 | |
| SCHEMBL4233740 | 0.90 | MCHR1 (0.39) | KDRFGFR1CCR3 | |
| SCHEMBL4238977 | 0.90 | MCHR1 (0.39) | FGFR1CCR3KIT | |
| SCHEMBL4233858 | 0.90 | SMN1; SMN2 (0.42) | RAF1KDRBRAFARAFABL1 | |
| SCHEMBL4688148 | 0.89 | CCR3 (0.49) | EPHX2RAF1UBE2MDCUN1D1KDR | |
| SCHEMBL4233894 | 0.89 | MCHR1 (0.47) | KDRFGFR1 | |
| SCHEMBL4237817 | 0.89 | PNLIP (0.42) | UBE2MDCUN1D1 | |
| SCHEMBL4236062 | 0.89 | MCHR1 (0.47) | KDRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | EPHX2 1515/4885RAF1 2279/4885UBE2M 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.